An investigation carried out by the Dana-Farber Cancer InstituteIn the United States, they have shown how the drug MK-6482 could slow the development of Kidney cancer.
MK-6482 is a key molecular driver in metastatic disease and achieves a 24 percent response rate in patients who receive it. This drug acts on the inducing factor of hypoxia (HIF) 2-a, a factor that promotes the growth of new blood vessels that feed kidney tumors and thus promote their development.
The study published in Journal of Clinical Oncology The study included 55 patients with advanced kidney cancer who had received at least three treatments prior to the study. Of these, 44 were men, and the average age of the participants was 62 years. They were followed for 13 months, and the overall response rate was 24 percent. Ultimately, tumor shrinkage occurred in 38 of the 55 patients (69 percent).
According to experts, the drug targets the mechanism that detects the body's oxygen levels and activates the genes that allow the body to adapt to hypoxia. This reaction leads to the production of more red blood cells and the formation of new blood vessels. Therefore, by acting on this mechanism, it could slow the development of blood vessels and thus prevent metastasis. Finally, they explain that its use could be promising even in patients who have previously received treatments without positive results.
ICUA Team
